Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion—a placebo-controlled study in healthy volunteers

ABSTRACT

 

Background: 

The new tablet formulation of omeprazole (Losec MUPS), is thought to have a stronger acid inhibition than the previously marketed capsules.

 

Methods: 

The effects of the proton pump inhibitors lansoprazole and omeprazole tablets on pentagastrin-stimulated acid secretion were compared in Helicobacter pylori-negative healthy male volunteers (n=12). The study was placebo-controlled, crossover matched and double-blind for lansoprazole (Agopton) and placebo, and single-blind for omeprazole tablets. Gastric acid response to sub-maximal pentagastrin-stimulation (0.6 μg · h/kg b.w.) was determined from 12.5 to 14.5 h after the first and second dose of the test drugs.

 

Results: 

Lansoprazole 15 mg and 30 mg as well as omeprazole 20 mg tablets caused a marked decrease in gastric acid secretion, showing equipotency for 15 mg lansoprazole and 20 mg omeprazole tablets. Their efficacy, however, was lower than 30 mg lansoprazole. In addition, the inter-individual variation after omeprazole tablets was higher than following lansoprazole. Neither 7.5 mg lansoprazole nor 10 mg omeprazole tablets were clearly different from placebo on the first 2 days.

The drugs were well-tolerated. No clinically relevant influence was found on either laboratory screen or cardiovascular parameters.

 

Conclusion: 

Lansoprazole 15–30 mg shows a stronger acid inhibition and a lower inter-individual variability than the new omeprazole 20 mg tablets on days 1 and 2 of dosing.